The Relation Between Modified Systemic Inflammation Score and Prognostic Markers of Gastrointestinal Stromal Tumors

Abstract

Objective
 Gastrointestinal stromal tumours are tumours of
 mesenchymal origin that can be located along
 the gastrointestinal tract. In this study, the role of
 Modified systemic inflammation score in predicting
 the prognosis of these tumours was investigated.
 Material and Method
 115 patients diagnosed with Gastrointestinal Stromal
 Tumor (GIST) who underwent surgery at Ankara City
 Hospital between June 1, 2019 and December 1,
 2022 were examined. Tumor location, size, presence
 of rupture-bleeding-necrosis, Ki-67 level, mitotic index
 and preoperative albumin, lymphocyte and monocyte
 levels were evaluated. mSIS score was grouped as
 0, 1 and 2. The relationship between mSIS and Ki-
 67 index and the presence of rupture, necrosis and
 bleeding was investigated.
 Results
 Out of 115 patients, 68 (59 %) were male, 47 (41 %)
 were female, with an average age of 62.5 (± 12.67)
 years. Tumor locations: stomach (64.3 %), small
 intestine (26 %), colon (5.2 %), esophagus (1.8 %),
 pancreas (1.8 %), and ovary (0.9 %). Necrosis was
 in 25 (30.7 %), hemorrhage in 67 (58.7 %), rupture
 in 19 (16.8 %), and the mean Ki-67 level was 9.09 (±
 10.64). 63 (54.8 %) patients had mSIS 0, 29 (25.2 %)
 had mSIS 1, and 23 (20 %) had mSIS 2. Statistical
 analysis found a significant correlation between mSIS
 and necrosis, but not with other parameters.
 Conclusion
 The mSIS score is a valuable score showing
 inflammation in the body and has been shown to be
 associated with the prognosis of many malignancies.
 In our study, the presence of necrosis in the tumour
 was found to be associated with the mSIS score.
 Although this result alone is not sufficient to predict
 the prognosis, it is thought to be an issue that may
 open the door to new studies.